5-aminolevulinic acid hexyl ester

structure in first source

Also Known As:

(14C)-hexaminolevulinate; 5-ALAHE; ALA hexyl ester; aminolevulinic acid hexylester; hexa ALA; hexaminolevulinate; hexaminolevulinate hydrochloride; hexyl-aminolevulinate; hexylaminolevulinate

Networked: 155 relevant articles (16 outcomes, 45 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Keto Acids: 203
    - Levulinic Acids
      - Aminolevulinic Acid: 819
        5-aminolevulinic acid hexyl ester: 155
Amino Acids, Peptides, and Proteins: 1
- Amino Acids: 30675
  - Aminolevulinic Acid: 819
    - 5-aminolevulinic acid hexyl ester: 155

Experts

1.	Stenzl, Arnulf: 11 articles (08/2021 - 12/2009)
2.	Witjes, J Alfred: 11 articles (04/2016 - 03/2005)
3.	Daneshmand, Siamak: 9 articles (01/2022 - 10/2014)
4.	Hillemanns, Peter: 9 articles (01/2022 - 03/2008)
5.	Malmström, Per-Uno: 8 articles (01/2019 - 07/2003)
6.	Grossman, H Barton: 8 articles (04/2016 - 07/2007)
7.	Lotan, Yair: 7 articles (01/2022 - 01/2018)
8.	Peng, Qian: 7 articles (06/2014 - 12/2005)
9.	Jocham, Dieter: 7 articles (11/2013 - 07/2003)
10.	Konety, Badrinath: 6 articles (01/2022 - 01/2017)

Related Diseases

1.	Non-Muscle Invasive Bladder Neoplasms 04/01/2013 - "Hexaminolevulinate hydrochloride may be cost effective when used at first TURB for patients with suspected new or recurrent non-muscle invasive bladder cancer." 07/01/2015 - "This study shows that improvement in diagnosis of NMIBC, mainly CIS and Ta tumours, obtained with BLC with hexaminolevulinate as an adjunct to WLC vs WLC alone can be shown in routine clinical practice." 01/01/2018 - "Blue light cystoscopy (BLC) using hexaminolevulinate (HAL/Cysview/Hexvix) has been previously shown to improve detection of non-muscle-invasive bladder cancer (NMIBC). " 01/01/2017 - "Improved diagnosis and long-term recurrence rate reduction for non-muscle-invasive bladder cancer patients undergoing fluorescent hexylaminolevulinate photodynamic diagnosis." 11/01/2014 - "Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology."
2.	Urinary Bladder Neoplasms (Bladder Cancer) 07/01/2012 - "Hexaminolevulinate fluorescence cystoscopy significantly improves long-term bladder cancer time to recurrence with a trend toward improved bladder preservation." 11/01/2010 - "We assessed the impact that improved detection of nonmuscle invasive bladder cancer with hexaminolevulinate fluorescence cystoscopy may have on early recurrence rates. " 09/01/2005 - "Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study." 09/01/2023 - "Blue light transurethral resection and biopsy of bladder cancer with hexaminolevulinate: Histopathological characteristics and recurrence rates in a single UK centre study." 01/01/2022 - "Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study."
3.	Neoplasms (Cancer) 08/01/2021 - "Photodynamic diagnosis using hexaminolevulinate (HAL)-guided BL-TURB may reduce the recurrence risk in non-muscle invasive BCa compared to standard WL-TURB due to more sensitive tumor detection. " 01/01/2021 - "Improving hexaminolevulinate enabled cancer cell detection in liquid biopsy immunosensors." 04/04/2020 - "It has been firmly established that hexaminolevulinate-assisted blue light cystoscopy (HAL-BLC) reduces cancer recurrence rates. " 11/01/2017 - "To evaluate the feasibility of hexaminolevulinate (HAL) for the photodynamic detection of cancer cells in voided urine. " 04/01/2015 - "Photodynamic diagnosis after instillation of hexylaminolevulinate (Hexvix(®)) during transurethral resection of the bladder (TURB) helps in the detection of tumors and results in a reduction of recurrence. "
4.	Carcinoma in Situ 11/01/2013 - "The hexyl aminolevulinate cystoscopy allows to identify a significantly greater number of lesions, including carcinoma in situ, compared to conventional white light cystoscopy. " 01/01/2004 - "Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy." 11/22/2010 - "To evaluate fluorescence cystoscopy with hexaminolevulinate (HAL) in the early detection of dysplasia (DYS) and carcinoma in situ (CIS) in select high risk patients. " 07/01/2007 - "Of a total of 113 carcinoma in situ lesions in 58 patients 104 (92%) were detected by hexaminolevulinate cystoscopy and 77 (68%) were detected by white light cystoscopy, while 5 were detected only on directed visually normal mucosal biopsy. " 07/01/2007 - "Overall more carcinoma in situ lesions were found by hexaminolevulinate than by white light cystoscopy in 22 of 58 patients (41.5%), while the converse occurred in 8 of 58 (15.1%). "
5.	Residual Neoplasm 04/01/2010 - "Compared with standard white-light cystoscopy, photodynamic diagnosis with blue light and the photosensitiser hexaminolevulinate has been shown to improve the visualisation of bladder tumours, reduce residual tumour rates by at least 20%, and improve recurrence-free survival. " 12/27/2022 - "Our study aimed to evaluate the impact of hexaminolevulinate Photodynamic Diagnostics (PDD) at first TURB on the rate of residual tumour. " 05/01/2019 - "The aim of our study was to assess the impact of blue light cystoscopy with hexaminolevulinate on residual tumor rates at second-look transurethral resection of the bladder (TURB). " 12/01/2022 - "The following results were found independent of age, gender and histological findings: Residual tumour rate: blue light group 13.95 % vs. white light group 32.6 %, (p 0.02, OR 3.8, CI 95 % [1.17 - 12.85]).; 3-month relapse-free survival: blue light group 87.7 % vs. white light group 67.4 % (p 0.02, HR 3.18, CI 95 % [1.20 - 8.42]); 1-year relapse-free survival: blue light group 77.6 % vs. white light group 55.1 % (p 0.015, HR 2.56, CI 95 % [1.20 - 5.45]); 1-year progression-free survival: blue light group 95.9 % vs. white light group 79.6 %, p 0.03, HR 5.23, CI 95 % [1.11 - 24.53]) CONCLUSION: The use of hexaminolevulinate significantly reduces the risk of residual tumours compared with conventional TURB. " 12/01/2009 - "Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors."

Related Drugs and Biologics

1.	1-phenyl-3,3-dimethyltriazene (PDT)
2.	protoporphyrin IX
3.	Doxorubicin (Adriamycin)
4.	Acids
5.	Porphyrins
6.	Esters
7.	Mitomycin (Mitomycin-C)
8.	Fluorescent Dyes (Fluorescent Probes)
9.	alanylalanine (Ala-Ala)
10.	Aminolevulinic Acid (Levulan)

Related Therapies and Procedures

1.	Photochemotherapy (Photodynamic Therapy)
2.	Transurethral Resection of Bladder
3.	Cystectomy
4.	Therapeutics
5.	Intravesical Administration